Volume 19 Issue 3
Mar.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(3): 410-412
TONG Jing-wei, LIU Xian-fu, ZHU Jing-wei, XU Pei-quan. Clinicopathological analysis of 9 patients with metaplastic breast carcinoma[J]. Chinese Journal of General Practice, 2021, 19(3): 410-412. doi: 10.16766/j.cnki.issn.1674-4152.001823
Citation: TONG Jing-wei, LIU Xian-fu, ZHU Jing-wei, XU Pei-quan. Clinicopathological analysis of 9 patients with metaplastic breast carcinoma[J]. Chinese Journal of General Practice, 2021, 19(3): 410-412. doi: 10.16766/j.cnki.issn.1674-4152.001823
shu

Clinicopathological analysis of 9 patients with metaplastic breast carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.001823

  • Surgical Oncology of Thyroid and Breast (Ward 2), the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui 233004, China

Funds:

 KJ2019A0341

  • Received Date: 2020-04-13
    Available Online: 2022-02-19
    Abstract
  •   Objective  Metaplastic breast cancinoma (MBC) is a very rare form of breast cancer. This study aimed to analyze the clinicopathologyic features and prognosis of MBC.  Methods  The clinicopathological data of 9 patients with MBC admitted to the First Affiliated Hospital of Bengbu Medical College from January 2011 to October 2019 were retrospectively reviewed, and the pathological characteristics, treatment and prognosis were summarized.  Results  All nine cases were women aged 46-60 years with median age of 49 years. The size of tumor was 1.0 to 4.5 cm, there was no obvious specificity in all imaging examination. Lymph node metastasis was found in 4 cases. Clinical stages: 3 cases of stage Ⅰ, 5 cases of stage Ⅱ and 1 cases of stage Ⅲ. All 9 cases were with negative hormone receptor, and 1 case was with positive for CerbB-2 receptor. The modified radical mastectomy was performed in 8 patients, and the simple breast resection plus sentinel lymph node biopsy was performed in 1 patient. Eight patients received postoperative adjuvant chemotherapy. Among them, there were 4 patients with chemotherapy regimen, 1 patient with AT chemotherapy regimen, 1 patient with PA chemotherapy regimen, 1 patient with TP chemotherapy regiment, 1 patient with E C chemotherapy regime plus capecitabine due to docetaxel allergy. Two patients received postoperative radiotherpy. One patient did not receive postoperative chemoradiotherapy due to age and physical reasons. Three cases had a recurrence, 1 case died from cancer.  Conclusion  The MBC is a rare malignant tumor of breast cancer that dose not has special imaging features, complex and diverse tissue components, negative hormone receptors and CerbB-2, and poor biological behavior and prognosis. Currently, there is no standard treatment plan. Therefore, further research on metastatic breast cancer may lead to the discovery of new and potentially effective treatment regimens, and ultimately improve the prognosis of these patients.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    EI ZEIN D, HUGHES M, KUMAR S, et al. Metaplastic carcinoma of the breast is more aggressive than triple-negative breast cancer: a study from a single institution and review of literature[J]. Clin Breast Cancer, 2017, 17(5): 382-391. doi: 10.1016/j.clbc.2017.04.009
    [2]
    BIAN T, LIN Q, WU Z, et al. Metaplastic carcinoma of the breast: imaging and pathological features[J]. Oncol Lett, 2016, 12(5): 3975-3980. doi: 10.3892/ol.2016.5177
    [3]
    张煜, 王墨培. 化生性乳腺癌的研究进展[J]. 癌症进展, 2019, 17(19): 2237-2238, 2263. https://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201919002.htm
    [4]
    FAYAZ S, DEMIAN G A, EISSA H E, et al. Metaplastic breast carcinoma: Analysis of 31 cases from a single institute[J]. J Egypt Natl Canc Inst, 2017, 29(3): 141-145. doi: 10.1016/j.jnci.2017.05.002
    [5]
    周平, 林冰, 李岩岩, 等. 化生性乳腺癌的临床病理特征及预后分析[J]. 海南医学院学报, 2019, 25(15): 1152-1156. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYY201915007.htm
    [6]
    王东存, 陈珂瑶, 唐兆瑞, 等. 乳腺化生性癌1例报道[J]. 诊断病理学杂志, 2017, 24(7): 539-541. doi: 10.3969/j.issn.1007-8096.2017.07.017
    [7]
    MCMULLEN E R, ZOUMBEROS N A, KLEER C G. Metaplastic breast carcinoma: update on histopathology and molecular alterations[J]. Arch Pathol Lab Med, 2019, 143(12): 1492-1496. doi: 10.5858/arpa.2019-0396-RA
    [8]
    GONZÁLEZ-MARTÍNEZ S, PÉREZ-MIES B, CARRETERO-BARRIO I, et al. Molecular features of metaplastic breast carcinoma: an infrequent subtype of triple negative breast carcinoma[J]. Cancers(Basel), 2020, 12(7): 1832. http://www.researchgate.net/publication/342846669_Molecular_Features_of_Metaplastic_Breast_Carcinoma_An_Infrequent_Subtype_of_Triple_Negative_Breast_Carcinoma
    [9]
    穆馥婷, 李斌, 秦优优, 等. 化生性乳腺癌的临床病理特点及诊疗现状[J]. 现代肿瘤医学, 2018, 26(12): 1958-1961. doi: 10.3969/j.issn.1672-4992.2018.12.040
    [10]
    TRAY N, TAFF J, ADAMS S. Therapeutic landscape of metaplastic breast cancer[J]. Cancer Treat Rev, 2019, 79(9): 1145-1156. http://www.sciencedirect.com/science/article/pii/S0305737219300957
    [11]
    胡紫玥, 卢漫, 成雪晴, 等. 化生性乳腺癌的超声及超声造影特征分析[J]. 中国超声医学杂志, 2019, 35(9): 783-785. doi: 10.3969/j.issn.1002-0101.2019.09.005
    [12]
    GAHLAUT R, BENNETT A, FATAYER H, et al. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression-lmplications for the practising oncologist[J]. Eur J Cancer, 2016, 60(6): 40-48. http://www.researchgate.net/profile/Abeer_Shaaban/publication/299996604_Original_Research_Effect_of_neoadjuvant_chemotherapy_on_breast_cancer_phenotype_ERPR_and_HER2_expression_e_Implications_for_the_practising_oncologist/links/5707cbe308ae2eb9421bd922.pdf
    [13]
    刘方方, 朱慧庭. 乳腺化生性癌[J]. 现代肿瘤医学, 2016, 24(17): 2805-2807. doi: 10.3969/j.issn.1672-4992.2016.17.040
    [14]
    TZANNINIS I G, KOTTEAS E A, NTANASIS-STATHOPOULOS I, et al. Management and outcomes in metaplastic breast cancer[J]. Clin Breast Cancer, 2016, 16(6): 437-443. doi: 10.1016/j.clbc.2016.06.002
    [15]
    王丽娜, 吴军召, 黄涛, 等. 女性乳腺化生性癌32例临床病理特征及预后影响因素分析[J]. 中华肿瘤防治杂志, 2020, 27(1): 58-62, 70. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL202001014.htm
    [16]
    BEVERS T B, HELVIE M, BONACCIO E, et al. Breast cancer screening and diagnosis, Version 3.2018, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2018, 16(11): 1362-1389. doi: 10.6004/jnccn.2018.0083
    [17]
    曾静, 张希梅, 王军, 等. 乳腺化生性癌临床病理特点及预后影响因素分析[J]. 中华肿瘤防治杂志, 2018, 25(2): 118-125. https://www.cnki.com.cn/Article/CJFDTOTAL-QLZL201802007.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (252) PDF downloads(3) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return